



## Un-Quantified Return On Investment

Potential investors in **Immunotech's** project stand to gain immediate benefits the moment their investments are consummated due to the following given criteria:

- 1- **Immunotech's** HIV/AIDS Project is not a concept, but has reached the final stages of a product. Unlike other Biotech start ups, we have completed the challenging criteria of bringing a concept to a molecule and following up until it has reached the final stages of its maturity to enter the regulatory/compliance phase.
- 2- The above process usually can be translated to an average of 7 to 10 years of Research & Development for the tune of a ballpark figure of \$400 million plus.
- 3- Current **Immunotech** founders have to date expanded a significant amount of their own time and finances, and are full time committed to the project's ultimate success.
- 4- **Immunotech's** product is being positioned for market entry as a complimentary treatment rather than a mono therapy. We are confident that with dosage optimization and a better understanding of data interpretation between PCR and PBMC assays, our product can stand alone as a mono therapy. Yet we are positioning ourselves for market entry through a major Pharma/Biotech entity, monopolizing on immediate manufacturing and distribution capabilities.
- 5- Analysts have estimated the Licensing fee, after Phase II trials, to be Mid Nine Figures with a royalty fee of 10-15 %.
- 6- Gross sales of IPF is expected to be close to 250 million dollars and plus annually. The net income generated for **Immunotech**, *based on royalties agreed upon*, should be in the range of 25 to 30 million dollars, annually.